Test ID: PYRC Pyruvate, Spinal Fluid
Reporting Name
Pyruvic Acid, CSFUseful For
Investigating possible disorders of mitochondrial metabolism, when used in conjunction with cerebrospinal fluid lactate, collected at the same time, to determine the lactate-to-pyruvate (L:P) ratio
Evaluating patients with neurologic dysfunction and normal blood L:P ratios
Specimen Type
CSFAdditional Testing Requirements
This test does not calculate the lactate:pyruvate ratio. To obtain this information, both this test and LASF1 / Lactic Acid, Spinal Fluid must be ordered. The ratio can be calculated from the results obtained from these tests.
Specimen Required
Specimen Type: Spinal fluid
Container/Tube: Sterile vial
Specimen Volume: 0.6 mL
Collection Instructions: Send specimen from vial 4.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 7 days | |
Frozen | 14 days | ||
Ambient | 7 days |
Reference Values
0.06-0.19 mmol/L
Day(s) Performed
Monday, Wednesday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
84210
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PYRC | Pyruvic Acid, CSF | 14122-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
83356 | Pyruvic Acid, CSF | 14122-6 |
Genetics Test Information
The cerebrospinal fluid lactate:pyruvate (L:P) ratio is considered a helpful (not diagnostic) tool in the evaluation of patients with possible disorders of mitochondrial metabolism, especially in patients with neurologic dysfunction and normal blood L:P ratios. Pyruvic acid levels alone have little clinical utility.
Clinical Information
Pyruvic acid, an intermediate metabolite, plays an important role in linking carbohydrate and amino acid metabolism to the tricarboxylic acid cycle, the fatty acid beta-oxidation pathway, and the mitochondrial respiratory chain complex. Though pyruvate is not diagnostic in itself, analysis with lactate has diagnostic value as many inborn errors of metabolism present with laboratory findings that include lactic acidosis and/or a high lactate:pyruvate (L:P) ratio.
The L:P ratio is elevated in several, but not all, mitochondrial respiratory chain disorders. Mitochondrial disorders vary widely in presentation and age of onset. Many mitochondrial disorders have neurologic and myopathic features and may involve multiple organ systems. Determination of lactate, pyruvate, and the L:P ratio in cerebrospinal fluid is helpful in directing attention toward a possible mitochondrial disorder in cases with predominantly neurologic dysfunction and normal blood lactate levels.
A low L:P ratio is observed in inherited disorders of pyruvate metabolism including pyruvate dehydrogenase complex (PDHC) deficiency. Clinical presentation of PDHC deficiency can range from fatal congenital lactic acidosis to relatively mild ataxia or neuropathy. The most common features in infants and children with PDHC deficiency are delayed development and hypotonia. Seizures and ataxia are also frequent features. Other manifestations can include congenital brain malformations, degenerative changes including Leigh disease, and facial dysmorphism.
Interpretation
An elevated lactate-to-pyruvate (L:P) ratio may indicate inherited disorders of the respiratory chain complex, tricarboxylic acid cycle disorders and pyruvate carboxylase deficiency. Respiratory chain defects usually result in L:P ratios above 20.
A low L:P ratio (disproportionately elevated pyruvic acid) may indicate an inherited disorder of pyruvate metabolism. Defects of the pyruvate dehydrogenase complex result in L:P ratios below 10.
The L:P ratio is characteristically normal in other patients. An artifactually high ratio can be found in acutely ill patients.
Clinical Reference
1. Munnich A, Rotig A, Cormier-Daire V, Rustin P. Clinical presentation of Respiratory Chain Deficiency. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed September 11, 2023. Available at http://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225086827
2. Robinson BH: Lactic acidemia. Disorders of pyruvate carboxylase and pyruvate dehydrogenase. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed September 11,, 2023. Available at http://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225087140
3. Shoffner JM. Oxidative phosphorylation diseases. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill. Accessed September 11, 2023. Available at http://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225088339
4. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17(9):689-701. doi:10.1038/gim.2014.177
Report Available
4 to 8 daysMethod Name
Spectrophotometry (SP)
Forms
1. Biochemical Genetics Patient Information (T602)
2. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Testing Algorithm
For more information see: Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
mcl-bgltestmenu